Imlunestrant: First Approval de réir Susan J. Keam (6594447)

Ábhair:

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Canc... de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2⁺ Breast Cancer de réir Jamunarani Veeraraghavan (16461809)

Ábhair:

Data Sheet 1_Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.xlsx de réir Andrea Aran (11711939)

Ábhair:

Supplementary file 1_Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.docx de réir Andrea Aran (11711939)

Ábhair:

Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine de réir Karama Asleh (15030080)

Ábhair:

Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States de réir Laura E. Stevens (14961009)

Ábhair:

Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer de réir Erwei Zeng (14958443)

Ábhair:

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States de réir Laura E. Stevens (14961009)

Ábhair:

Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States de réir Laura E. Stevens (14961009)

Ábhair:

Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer de réir Erwei Zeng (14958443)

Ábhair:

Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States de réir Laura E. Stevens (14961009)

Ábhair:

Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States de réir Laura E. Stevens (14961009)

Ábhair:

Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer de réir Erwei Zeng (14958443)

Ábhair:

Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer de réir Erwei Zeng (14958443)

Ábhair: